Stockreport

Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF BDC-1001 program advances in multiple Phase 2 clinical studies in patients with HER2-positive colorectal, gastric, endometrial, and metastatic breast cancer, with recent [Read more]